PMID- 33505115
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220202
IS  - 0920-9069 (Print)
IS  - 1573-0778 (Electronic)
IS  - 0920-9069 (Linking)
VI  - 73
IP  - 1
DP  - 2021 Feb
TI  - The inhibition of HeLa cells proliferation through SPARCL1 mediated by SPP1.
PG  - 71-78
LID - 10.1007/s10616-020-00443-2 [doi]
AB  - Secreted protein acidic and rich in cysteines-like 1 (SPARCL1) is implicated in 
      tumor progression and considered as a tumor suppressor. Aim of the study is to 
      investigate the role of SPARCL1 in the regulation of tumor biology. SPARCL1 
      expression in human cervical cells was determined through western blot and 
      RT-PCR. The effects of SPARCL1 overexpression on cell proliferation, migration 
      and invasion were evaluated through CCK8 assay, colony formation assay, Wound 
      healing assay and Transwell assay, respectively. The gain function of Secreted 
      phosphor protein 1 (SPP1) was also evaluated in these cell functions. We observed 
      that SPARCL1 expression at protein levels and transcription levels was lower in 
      HeLa cells than that in Ect1/E6E7 cells. When SPARCL1 was overexpressed in HeLa 
      cells, cell proliferation, migration and invasion were greatly repressed. 
      Additionally, SPARCL1 overexpression markedly downregulated SPP1 expression at 
      transcription levels. Mechanistical study revealed that SPP1 overexpression could 
      greatly counteract the effects of SPARCL1 overexpression on the aforementioned 
      cell processes and inhibit the phosphorylation of focal adhesion kinase (FAK) and 
      extracellular regulated protein kinases (ERK). Our findings indicated that HeLa 
      cells overexpressing SPARCL1 showed weaker abilities of proliferation, migration 
      and invasion, and its effects could be neutralized by SPP1 overexpression 
      possibly via FAK/ERK pathway. The relationship of SPARCL1 and SPP1 could help us 
      to further understand the pathogenesis of cervical cancer and SPARCL1/SPP1 could 
      be beneficial therapeutic targets in cervical cancer.
CI  - (c) The Author(s), under exclusive licence to Springer Nature B.V. part of Springer 
      Nature 2021.
FAU - Zhang, Shengpeng
AU  - Zhang S
AD  - Department of Obstetrics and Gynecology, Beijing Tiantan Hospital, Capital 
      Medical University, No. 119 South Fourth Ring West Road, Fengtai District, 
      Beijing, 100070 P.R. China. GRID: grid.24696.3f. ISNI: 0000 0004 0369 153X
FAU - Zhang, Fengge
AU  - Zhang F
AD  - Department of Obstetrics and Gynecology, Shunyi Maternal and Children's Hospital 
      of Beijing Children's Hospital, Beijing, 101300 P.R. China. GRID: grid.411609.b
FAU - Feng, Limin
AU  - Feng L
AD  - Department of Obstetrics and Gynecology, Beijing Tiantan Hospital, Capital 
      Medical University, No. 119 South Fourth Ring West Road, Fengtai District, 
      Beijing, 100070 P.R. China. GRID: grid.24696.3f. ISNI: 0000 0004 0369 153X
LA  - eng
PT  - Journal Article
DEP - 20210103
PL  - United States
TA  - Cytotechnology
JT  - Cytotechnology
JID - 8807027
PMC - PMC7817754
OTO - NOTNLM
OT  - Cervical cancer
OT  - FAK/ERK
OT  - SPARCL1
OT  - SPP1
COIS- Conflict of interestAll authors declare no conflict of interest.
EDAT- 2021/01/29 06:00
MHDA- 2021/01/29 06:01
PMCR- 2022/02/01
CRDT- 2021/01/28 05:41
PHST- 2020/10/14 00:00 [received]
PHST- 2020/11/19 00:00 [accepted]
PHST- 2021/01/28 05:41 [entrez]
PHST- 2021/01/29 06:00 [pubmed]
PHST- 2021/01/29 06:01 [medline]
PHST- 2022/02/01 00:00 [pmc-release]
AID - 443 [pii]
AID - 10.1007/s10616-020-00443-2 [doi]
PST - ppublish
SO  - Cytotechnology. 2021 Feb;73(1):71-78. doi: 10.1007/s10616-020-00443-2. Epub 2021 
      Jan 3.